DescriptionInnovations and advances in the field of PD — including evaluation, treatment, and prevention — continue to occur at a rapid pace, challenging both specialists and generalists to stay abreast of the changes, creating gaps in knowledge, competence, and practice among health care providers. In many cases, the data are not clear regarding the clinical implications. In turn, this creates a pressing need for educational activities focused on providing updates and critical analyses of both the pros and cons of the most recent advances in the care of patients with PD.
Directors & Faculty
Hubert Fernandez, MD, FAANCleveland Clinic Michael Schwarzchild, MD, PhDMassachusetts General Hospital
Roy Alcalay, MD, MSColumbia University Helen Bronte-Stewart, MD, MSStanford University Susan Fox, MRCP, PhDUniversity of Toronto Joohi Jimenez-Shahed, MDIcahn School of Medicine at Mount Sinai Peter Lewitt, MDHenry Ford Hospital Zoltan Mari, MDCleveland Clinic Aristide Merola, MD, PhDThe Ohio State University Tiago Mestre, MD, MScUniversity of Ottawa Martha Nance, MDStruthers Parkinson's Center William Ondo, MDMethodist Hospital Houston Fernando Pagan, MDGerogetown University Gregory Pontone, MD, MHSThe Johns Hopkins Hospital Liana Rosenthal, MD, PhDThe Johns Hopkins Hospital Marie Saint-Hilaire, MD, MRCP(C), FAANBoston University Andrew Siderowf, MD, MSCEUniversity of Pennsylvania Tanya Simuni, MDNorthwestern University Allison Willis, MD, MSUniversity of Pennsylvania Anne-Marie Wills, MD, MPHMassachusetts General Hospital Michele York, PhD, ABPP-CNBaylor College of Medicine
After completing this activity, the participant will be able to do the following:
- List the most recent insights from studies investigating the role of genetic targets in disease- modifying therapies for Parkinson disease.
- Discuss how COVID-19 has promoted telemedicine for follow-up care of patients with Parkinson disease as well as its impact on clinical trial design.
- Summarize the evidence supporting the efficacy of behavioral and nonmotor therapies for Parkinson disease.
- Critically assess the outcomes and issues when comparing closed-loop technology against directional leads for deep brain stimulation.
- Describe the available neuropsychological tests for detecting mild cognitive impairment in Parkinson disease and discuss the best timing of their use.
- List the options for short-acting rescue therapies in Parkinson disease and their potential use as on-demand therapy.
- Discuss the accuracy of the scale for measuring motor fluctuations in Parkinson disease in relation to its use as an outcome measure in symptomatic trials.
Disclosures and Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Parkinson Study Group. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this internet live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
For the purposes of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™
issued by organizations accredited by the ACCME.